Evidence map›Paper›PMID 40252649›Full record

ArticleMolecular cell2025

The SWI/SNF PBAF complex facilitates REST occupancy at repressive chromatin.

Elena Grossi, Christie B Nguyen, Saul Carcamo, Valentina Kirigin Callaú, Shannon Moran, Dan Filipescu, Somnath Tagore, Tessa M Firestone, Michael-Christopher Keogh, Lu Sun and 3 more

Abstract read
In one paragraph

Article in Molecular cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Elena GrossiDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: elena.grossi@mssm.edu.
Christie B NguyenDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Saul CarcamoTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Bioinformatics for Next Generation Sequencing (BiNGS) Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Valentina Kirigin CallaúDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Shannon MoranDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Dan FilipescuDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Somnath TagoreDepartment of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.
Tessa M FirestoneEpiCypher Inc., Durham, NC 27709, USA.
Michael-Christopher KeoghEpiCypher Inc., Durham, NC 27709, USA.
Lu SunEpiCypher Inc., Durham, NC 27709, USA.
Benjamin IzarDepartment of Medicine, Division of Hematology/Oncology, and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA.
Dan HassonDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Bioinformatics for Next Generation Sequencing (BiNGS) Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Emily BernsteinDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: emily.bernstein@mssm.edu.

Funding

THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4M
Studying the evolution of drug resistance in prostate cancer at the single cell levelU54CA274506 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Peter Alan Sims · 2023 to 2026
$9.1M
Skin Biology and Diseases Resource-based Center at Mount SinaiP30AR079200 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Elena Ezhkova · 2021 to 2026
$5.2M
Deciphering the tumor suppressive functions of macroH2AR01CA154683 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BERNSTEIN, EMILY · 2011 to 2021
$3.9M
Mechanisms of liver metastasis and associated resistance to immunotherapyR37CA258829 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Benjamin Izar · 2021 to 2026
$2.6M
Development of efficient quantitative chromatin profiling in kit and high-throughput formatsR44HG010640 · NHGRI · EPICYPHER, INC. · PI KEOGH, MICHAEL-CHRISTOPHER, VENTERS, BRYAN J · 2020 to 2022
$2.4M
Development of novel spike-in controls for quantitative chromatin-associated protein profilingR44DE029633 · NIDCR · EPICYPHER, INC. · PI KEOGH, MICHAEL-CHRISTOPHER, VENTERS, BRYAN J · 2019 to 2021
$2.2M
The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapyR01CA266446 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FRANGIEH, CHRISTOPHER · 2022 to 2025
$2.0M
COVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0M
Big Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0M
Elucidating the role of REST in shaping the epigenome of melanomaF30CA253988 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI NGUYEN, CHRISTIE BAO THU · 2020 to 2023
$191k
NCI NIH HHS F30 CA253988NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA154683NCI NIH HHS R01 CA266446NCI NIH HHS R37 CA258829NCI NIH HHS U54 CA274506NHGRI NIH HHS R44 HG010640NIAMS NIH HHS P30 AR079200NIDCR NIH HHS R44 DE029633NIH HHS S10 OD026880NIH HHS S10 OD030463
6 · The paper itself

Abstract

SWI/SNF (switch/sucrose non-fermentable) chromatin remodelers possess unique functionalities difficult to dissect. Distinct cancers harbor mutations in specific subunits, such as the polybromo-associated BAF (PBAF)-specific component ARID2 in melanoma. Here, we perform epigenomic profiling of SWI/SNF complexes and their associated chromatin states in melanocytes and melanoma. Time-resolved approaches reveal that PBAF regions are generally less sensitive to ATPase inhibition than BAF sites. We further uncover a subset of PBAF-exclusive regions within Polycomb-repressed chromatin that are enriched for REST (RE1 silencing transcription factor), a transcription factor that represses neuronal genes. In turn, PBAF complex disruption via ARID2 loss hinders REST's ability to bind and inactivate its targets, leading to upregulation of synaptic transcripts. Remarkably, this gene signature is conserved in melanoma patients with ARID2 mutations and correlates with an expression program enriched in melanoma brain metastases. Overall, we demonstrate a unique role for PBAF in generating accessibility for a silencing transcription factor at repressed chromatin, with important implications for disease.

Indexed as

ChromatinChromatin Assembly and DisassemblyChromosomal Proteins, Non-HistoneMelanomaRepressor ProteinsTranscription FactorsAnimalsBrain NeoplasmsCell Line, TumorDNA-Binding ProteinsGene Expression Regulation, NeoplasticHumansMelanocytesMutationRE1-Silencing Transcription FactorARID2 protein, humanChromatinChromosomal Proteins, Non-HistoneDNA-Binding ProteinsRE1-Silencing Transcription FactorRepressor ProteinsSWI-SNF-B chromatin-remodeling complexTranscription FactorsARID2chromatin remodelersmelanomaPBAFPolycombRESTSWI/SNFtranscription factors

Identifiers

PMID40252649
PMCPMC12048221

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.